2025年6月12日，上海诗健生物科技有限公司与美国生物科技公司Sovran Bio, Inc.联合宣布签署战略合作协议。此次合作旨在整合Sovran在广谱疾病靶向领域的创新生物结构设计，与诗健生物自主研发的EZWi-Fit®平台技术及丰富的研发经验，以快速推进多款新型抗体及抗体药物偶联物（ADC）药物候选分子进入临床试验阶段。根据协议，双方将共同参与合作项目的研发，并共享合作成果带来的收益。

Sovran创始人兼CEO David Meininger博士表示：这次合作充分发挥了双方优势，能够迅速且高效地将针对常见治疗难题的新思路转化为对患者更优的解决方案。

诗健生物创始人兼CEO周清博士表示：此次合作是双方公司在加速研发进程及将新一代疗法推向全球医药市场方面的重大里程碑，联合研发模式也将为双方创造巨大全球机遇，释放协同创新潜力。

关于Sovran

SovranBio是一家致力于满足未被满足的医疗需求的生物医药研发公司。该公司正在探索针对任何癌症都可能适用的肿瘤抗原特异性的新方法。研发管线包括寻求应对疾病干预固有挑战的更多解决方案。

关于诗健生物

诗健是一家位于中国上海的临床阶段生物技术公司，聚焦创新ADC药物的开发。目前诗健最前端的Trop-2 ADC管线ESG401已进入三期临床试验。诗健新一代联接子-载荷技术平台EZWi-Fit®，在安全性、有效性、抗耐药性和药代动力学特征方面都具有显著的竞争优势。借助这一平台技术，诗健正在快速拓展针对新靶点或已验证靶点的ADC产品线，首款搭载EZWi-Fit®技术的 ADC 产品已成功启动首个人体临床试验。诗健也已经成功将此平台技术授权给国内和国际多家生物技术公司，赋能其创新ADC项目。

Escugen and Sovran Forge Strategic Partnership Announcement

June 12, 2025 — Shanghai Escugen Biotechnology Co., Ltd. and Sovran Bio, Inc. jointly announced today the signing of a strategic collaboration agreement. This collaboration aims to leverage Sovran's unique approach to broad-spectrum disease targeting and unique biologic architectures together with Escugen's proprietary EZWi-Fit® platform technology and deep development expertise to rapidly advance multiple novel antibody and antiody-drug conjugate (ADC) therapeutic product candidates to the clinical. Under the agreement, the parties will jointly contribute to partnered program research and development with shared upside.

Dr. David Meininger, Founder & CEO of Sovran, remarked that the deal plays to the strengths of each company to quickly and efficiently translate new thinking on well-known therapeutic problems into better solutions for patients.

Dr. Qing Zhou, Co-Founder and CEO of Escugen, stated that this partnership marks a significant milestone for both companies to accelerate their R&D processes in bringing next-generation therapeutics to the global pharmaceutical market. A joint research effort also harvests tremendous global opportunities for both parties. 

About Sovran

SovranBio is a biopharmaceutical research and development company dedicated to addressing unmet medical needs. The company is exploring novel approaches to tumor-antigen specificity potentially applicable to any cancer. Pipeline efforts include pursuit of additional solutions to challenges inherent to broad-spectrum targeting in oncology, autoimmunity and other disease areas.

About Escugen

Escugen is a clinical-stage biotechnology company located in Shanghai, China, focusing on the development of innovative ADC drugs. Currently, Escugen's lead Trop-2 ADC pipeline, ESG401, has entered Phase III clinical trials. Escugen's next-generation linker-payload technology platform, EZWi-Fit®, offers significant competitive advantages in terms of safety, efficacy, anti-multiple drug resistance, and pharmacokinetic characteristics. Leveraging this platform technology, Escugen is rapidly expanding its ADC pipeline targeting new or validated target. The first ADC product baring the EZWi-Fit® technology has successfully launched its FIH clinical campaign. In addition, Escugen has licensed this platform technology to several domestic and international biotechnology companies to empower their innovative ADC projects.